Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease where invasive
pulmonary myofibroblasts secrete collagen and destroy lung integrity. Here, we show that …

Fibrotic interstitial lung disease (ILD) represents a large group of pulmonary disorders that
are often progressive and associated with high morbidity and early mortality. Important …

Pirfenidone is one of two approved therapies for the treatment of idiopathic pulmonary
fibrosis (IPF). Randomised controlled clinical trials and subsequent post hoc analyses have …

Since December 2019, coronavirus disease (COVID‐19) has rapidly swept the world. So far,
more than 30 million people have been infected and nearly one million have died. Although …

Introduction Recent developments in the care of patients with idiopathic pulmonary fibrosis
have the potential to improve survival rates. Population-based estimates of the current …

Pulmonary fibrosis (PF) encompasses a spectrum of chronic lung diseases that
progressively impact the interstitium, resulting in compromised gas exchange …

Rationale: Respiratory-related hospitalizations of patients with idiopathic pulmonary fibrosis
(IPF) are more frequent than those for acute IPF exacerbations and are associated with poor …

Organ fibrosis is a process in which cellular homeostasis is disrupted and extracellular
matrix is excessively deposited. Fibrosis can lead to vital organ failure and there are no …

Lung transplantation (LTx) can be a life-extending treatment option for patients with
advanced and/or progressive fibrotic interstitial lung disease (ILD), especially idiopathic …

Rationale: Since their approval, there has been no real-world or randomized trial evidence
evaluating the effect of the antifibrotic medications pirfenidone and nintedanib on clinically …